Rezolute

RZLT

Market cap $318M

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints

LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates

RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.

In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.

REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.

NEW YORK--(BUSINESS WIRE)---- $RZLT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Rezolute, Inc. shares tumbled sharply on December 11, 202.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310).  [You may also click here for additional information] NEW YORK, March 5, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).